Medications Development for Cannabis-Related Disorders (R01)
ArchivedNational Institutes of Health
Description
Purpose. The purpose of this Funding Opportunity Announcement (FOA) is to issue a Request for Applications (RFA) to support research studies that focus on the identification, and preclinical and clinical evaluation, of medications that can be safe and effective for the treatment of cannabis-use and -induced disorders, as well as their medical and psychiatric consequences. The studies can be preclinical or FDA-defined Phase I, Phase II or Phase III clinical trials. Mechanism of Support. This FOA will utilize the R01 grant mechanism and runs in parallel with two FOAs of identical scientific scope, PA-07-365 and PA-07-366, that solicit applications under the R01 and R21 mechanisms, respectively. Funds Available and Anticipated Number of Awards. It is anticipated that a total of 6 awards will be funded for a total of $3,000,000.
Who can apply
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities / Indian housing authorities
- Native American tribal organizations (other than Federally recognized)
- Nonprofits with 501(c)(3) status (other than higher education)
- Nonprofits without 501(c)(3) status (other than higher education)
- Private institutions of higher education
- For-profit organizations other than small businesses
- Small businesses
- Others
Contact
NIH OER Webmaster<br/>FBOWebmaster@OD.NIH.GOV<br/>
FBOWebmaster@OD.NIH.GOV
- PostedSep 24, 2009
- ClosesApr 30, 2010
- Award ceiling$500,000
- Program funding$3,000,000
- Expected awards6
- CFDA93.279
Pro insight
Edit and export this grant’s proposal template, plus deadline reminders, similar-grant suggestions, and funder history — all available with Pro.
Unlock with Pro